The evolving survival landscape in advanced non-small cell lung cancer: an interrupted time series analysis

The introduction of targeted therapy and immunotherapy has produced significant survival improvement in adenocarcinoma, with the most pronounced benefits with immunotherapy. Treatment efficacy varies across subgroups highlighting the need for further investigation to optimize personalized therapy.